29 June 2023
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Results of AGM
Roquefort Therapeutics (LSE:ROQ, OTCQB: ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, is pleased to announce that at the Company's Annual General Meeting ("AGM") held earlier today, all resolutions proposed were duly passed.
The resolutions were put to shareholders via a poll, the results of which were as follows:
| Resolution | Poll Results | Total Votes Withheld* | |||
| For | Against | Total Votes Cast | |||
| 1 | Shares | 21,890,925 | - | 21,890,925 | - |
| % | 100.00% | - | |||
| 2 | Shares | 21,890,885 | 20 | 21,890,905 | 20 |
| % | 100.00% | 0.00% | |||
| 3 | Shares | 21,890,885 | 20 | 21,890,905 | 20 |
| % | 100.00% | 0.00% | |||
| 4 | Shares | 10,257,712 | 2,713 | 10,260,425 | 11,630,500 |
| % | 99.97% | 0.03% | |||
| 5 | Shares | 21,890,925 | - | 21,890,925 | - |
| % | 100.00% | - | |||
| 6 | Shares | 21,890,885 | 20 | 21,890,905 | 20 |
| % | 100.00% | 0.00% | |||
| 7 | Shares | 21,890,925 | - | 21,890,925 | - |
| % | 100.00% | - | |||
| 8 | Shares | 21,890,905 | 20 | 21,890,925 | - |
| % | 100.00% | 0.00% | |||
| 9 | Shares | 21,885,885 | 20 | 21,885,905 | 5,020 |
| % | 100.00% | 0.00% | |||
| 10 | Shares | 21,855,276 | 35,629 | 21,890,905 | 20 |
| % | 99.84% | 0.16% | |||
| 11 | Shares | 21,885,071 | 573 | 21,885,644 | 5,281 |
| % | 100.00% | 0.00% | |||
* Votes withheld are not counted in the calculation of the proportion of votes for and against a resolution.
The total number of ordinary shares in issue on 27 June 2023, the deadline for casting votes by proxy in advance of the AGM, was 129,149,998 shares. 17% of voting capital was instructed in respect of the resolutions put to the AGM.
Enquiries:
| Roquefort Therapeutics plc | |
| Stephen West (Chairman) / Ajan Reginald (CEO) | +44 (0)20 3918 8633
|
| Hybridan LLP (Joint Broker) Claire Louise Noyce
Optiva Securities Limited (Joint Broker) |
+44 (0)203 764 2341 |
| Christian Dennis
Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale
| +44 (0)20 3411 1881
+44 (0)20 7466 5000
|
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.
Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.
Roquefort Therapeutics' portfolio consists of five fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:
· Midkine antibodies with significant in vivo efficacy and toxicology studies;
· Midkine RNA therapeutics with novel anti-cancer gene editing action;
· Midkine mRNA therapeutics with novel anti-cancer approach;
· STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and
· MK cell therapy with direct and NK-mediated anti-cancer action
For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
